Phase 2Data readout

AKB-097 (Complement Inhibitor)

IgA Nephropathy, Lupus Nephritis, C3 Glomerulopathy

AKBAAkebia

Expected catalystDecember 31, 2027Company guidance: Dec 31, 2027

Catalyst overview

Event details

Drug or asset: AKB-097 (Complement Inhibitor)
Development stage: Phase 2
Event type: Data readout
Indication: IgA Nephropathy, Lupus Nephritis, C3 Glomerulopathy

Research summary

What is being tracked?

This catalyst tracks a Phase 2 data readout for AKB-097 (Complement Inhibitor) in IgA Nephropathy, Lupus Nephritis, C3 Glomerulopathy. The expected timing is based on the latest available company guidance and may change.

Development notes

08/05/26:- Ebribafusp Ph2 basket trial ongoing; up to 30 patients; initial 2027 data.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

Phase 2Data readout

AKB-097 (Complement Inhibitor)

IgA Nephropathy, Lupus Nephritis, C3 Glomerulopathy

AKBAAkebia

Expected catalystDecember 31, 2027Company guidance: Dec 31, 2027

Catalyst overview

Event details

Drug or asset: AKB-097 (Complement Inhibitor)
Development stage: Phase 2
Event type: Data readout
Indication: IgA Nephropathy, Lupus Nephritis, C3 Glomerulopathy

Research summary

What is being tracked?

Development notes

08/05/26:- Ebribafusp Ph2 basket trial ongoing; up to 30 patients; initial 2027 data.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

AKB-097 (Complement Inhibitor)

Event details

What is being tracked?

Development notes

Primary source

Related pipeline programs